Derivation of cutoffs for the Elecsys ® amyloid β (1-42) assay in Alzheimer's disease.

Leslie M Shaw,Teresa Waligorska,Leona Fields,Magdalena Korecka,Michal Figurski,John Q Trojanowski,Udo Eichenlaub,Simone Wahl,Marian Quan,Michael J Pontecorvo,D Richard Lachno, Jayne A Talbot,Scott W Andersen,Eric R Siemers,Robert A Dean

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring（2018）

引用 59|浏览75

暂无评分

摘要

•Biomarkers can facilitate appropriate patient recruitment into clinical trials.•Amyloid beta measurement can aid the identification of amyloid-positive patients.•Similar cutoff estimates were derived by three different approaches.

查看译文

关键词

Alzheimer's disease,Biomarkers,Immunoassay,Amyloid β,Cerebrospinal fluid,Method comparison,Florbetapir F 18 imaging,Cutoff determination,Patient selection

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要